<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000269133"><TermName>bortezomib</TermName><TermPronunciation>(bor-TEH-zoh-mib)</TermPronunciation><TermDefinition><DefinitionText>A drug used to treat multiple myeloma. It is also used to treat mantle cell lymphoma in patients who have already received at least one other type of treatment and is being studied in the treatment of other types of cancer. Bortezomib blocks several molecular pathways in a cell and may cause cancer cells to die. It is a type of proteasome inhibitor and a type of dipeptidyl boronic acid. Also called PS-341 and velcade.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000710188" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;bortezomib&quot;" language="en" id="_3"/><MediaLink ref="CDR0000710187" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;bortezomib&quot;" language="es" id="_4"/><SpanishTermName>bortezomib</SpanishTermName><SpanishTermDefinition><DefinitionText>Medicamento que se usa en el tratamiento del mieloma múltiple.  También se usa para tratar el linfoma de células de manto en pacientes que ya habían recibido al menos otro tipo de tratamiento y también está en estudio para el tratamiento de otros tipos de cáncer. El bortezomib interrumpe varios conductos moleculares en la célula y ocasiona la muerte celular. Es un tipo de inhibidor del proteasoma y de ácido borónico dipeptidilo. También se llama PS-341 y velcade.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2002-11-24</DateFirstPublished><DateLastModified>2009-11-10</DateLastModified><RelatedInformation><RelatedDrugSummaryRef href="CDR0000491682">Bortezomib</RelatedDrugSummaryRef></RelatedInformation></GlossaryTerm>
